

UNITED STATES PATENT AND TRADEMARK OFFICE

T

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/791,217		03/02/2004	Els A.J.M. Goulmy	2183-4285.1US	3284
24247	7590	05/25/2006		EXAMINER	
TRASK B	RITT		HUYNH, PHUONG N		
P.O. BOX 2550 SALT LAKE CITY, UT 84110				ART UNIT	PAPER NUMBER
0	,	,,		1644	
				DATE MAILED: 05/25/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Office Action Commence	10/791,217	GOULMY ET AL.					
Office Action Summary	Examiner	Art Unit					
	Phuong Huynh	1644					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE Three MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
Responsive to communication(s) filed on <u>27 Fe</u> This action is FINAL . 2b)⊠ This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro						
Disposition of Claims							
4) Claim(s) 12,14,15,17-19 and 22-27 is/are pend 4a) Of the above claim(s) is/are withdraw 5) Claim(s) 12,14,15,17,18,22-24,26 and 27 is/are 6) Claim(s) 19 and 25 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or Application Papers 9) The specification is objected to by the Examine 10) The drawing(s) filed on 02 March 2004 is/are: a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examine 11) The oath or declaration is objected to by the Examine 11) The oath or declaration is objected to by the Examine 11) The oath or declaration is objected to by the Examine 11) The oath or declaration is objected to by the Examine 11) The oath or declaration is objected to by the Examine 11 The oath or declaration is objected to by the Examine 11 The oath or declaration is objected to by the Examine 11 The oath or declaration is objected to by the Examine 11 The oath or declaration is objected to by the Examine 11 The oath or declaration is objected to by the Examine 12 The oath or declaration is objected to by the Examine 13 The oath or declaration is objected to by the Examine 14 The oath or declaration is objected to by the Examine 15 The oath or declaration is objected to by the Examine 15 The oath or declaration is objected to by the Examine 15 The oath or declaration is objected to by the Examine 15 The oath or declaration is objected to by the Examine 15 The oath or declaration is objected to by the Examine 15 The oath or declaration is objected to by the Examine 15 The oath or declaration is objected to by the Examine 15 The oath or declaration is objected to by the Examine 15 The oath or declaration is objected to by the Examine 15 The oath or declaration is objected to by the Examine 15 The oath or declaration is objected to by the Examine 15 The oath or declaration is objected to by the Examine 15 The oath or dec	vn from consideration. e allowed. r election requirement. r. a)⊠ accepted or b)□ objected to drawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa						

Application/Control Number: 10/791,217 Page 2

Art Unit: 1644

DETAILED ACTION

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/27/06 has been entered.

- 2. Claims 12, 14-15, 17-19, and 22-27 are pending.
- 3. The specification is objected to as failing to provide proper antecedent basis for the claimed subject matter. See 37 CFR 1.75(d)(1) and MPEP § 608.01(o). Correction of the following is required: The specification fails to provide antecedent basis for the term "immortalized" in original claim 17.
- 4. The listing of references in the specification at pages 28-31 is not a proper information disclosure statement.

The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, applications, or other information submitted for consideration by the Office, and MPEP § 609 subsection III A (1) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.

- 5. The following is a quotation of the first paragraph of 35 U.S.C. 112:
 - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 6. Claim 25 is rejected under 35 U.S.C. 112, first paragraph, containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.

Application/Control Number: 10/791,217 Page 3

Art Unit: 1644

The term "a gene that codes for herpes simplex virus thymidine kinase" in claim 25 represents a departure from the specification and the claims as originally filed. The specification at page 11 line 12 discloses the cytotoxic T-cell is transduced with a suicide gene. However, the specification does not disclose transduced the cytotoxic T cell with the specific gene that encodes for herpes simplex virus thymidine kinase. The passage at page 18 does not support said term.

- 7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.
- 8. Claim 19 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

"A cytotoxic T-cell" in claim 19 is indefinite because the term "A cytotoxic T cell" fails to define the specificity of the cytotoxic T cell. The specification at page 11, line 2 discloses only the peptide specific cytotoxic T cells. It is suggested that claim 19 be amended to recite "An isolated VLXDDLLEA peptide specific cytotoxic T cell..." to clearly define the cytotoxic T.

- 9. Claims 12, 14-15, 17-18, 22-24 and 26-27 are allowed.
- 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phuong Huynh "NEON" whose telephone number is (571) 272-0846. The examiner can normally be reached Monday through Friday from 9:00 am to 5:30 p.m. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The IFW official Fax number is (571) 273-8300.
- Any information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 10/791,217

Art Unit: 1644

Phuong N. Huynh, Ph.D.

Patent Examiner

Technology Center 1600

May 15, 2006

CHRISTINA CHAN
SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600